» Articles » PMID: 35483928

Update on Primary Plasma Cell Leukemia

Overview
Journal Blood Res
Publisher Springer Nature
Specialty Hematology
Date 2022 Apr 28
PMID 35483928
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma cell leukemia (PCL) is a rare and highly aggressive plasma cell neoplasm developing in 0.5?4% of patients with multiple myeloma (MM). The diagnostic criteria were recently revised from 20% to ≥5% of circulating plasma cells in peripheral blood smears. PCL is classified as primary or secondary; primary PCL is when it presents in patients with no MM. Primary PCL shows clinical and laboratory features at presentation that differ from MM and exhibits a dismal prognosis even with the use of effective agents against MM. Therefore, intensive chemotherapy should be initiated immediately after diagnosis, and autologous stem cell transplantation is recommended for transplant-eligible patients. Maintenance therapy after transplantation may reduce the rate of early relapses. We reviewed the definitions of PCL, revised diagnostic criteria, clinical features, and appropriate initial treatments for primary PCL.

Citing Articles

Selinexor in combination with pomalidomide and dexamethasone for the treatment of primary plasma cell leukemia with 1q21+ abnormality: A case report.

Fan W, Wang L, Wang X, Liu Y, Sun M, Abduklimu N Medicine (Baltimore). 2024; 103(46):e40447.

PMID: 39560551 PMC: 11575965. DOI: 10.1097/MD.0000000000040447.


A Case of Plasma Cell Leukemia Arising De Novo: A Rare and Fatal Disease.

Sweidan H, Jarrah A, Zhu F, Wang Y Cureus. 2024; 16(10):e71393.

PMID: 39403422 PMC: 11471913. DOI: 10.7759/cureus.71393.


Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review.

Elsabah H, Ghasoub R, El Omri H, Benkhadra M, Cherif H, Y Taha R Front Oncol. 2024; 14:1390747.

PMID: 39050574 PMC: 11266074. DOI: 10.3389/fonc.2024.1390747.


Improved Outcome of Primary Plasma Cell Leukemia in the Current Era with the Use of Novel Agents and Autologous Bone Marrow Transplants-A Single Centre Experience.

Gupta D, Moule P, Aggarwal C, Kotwal J, Langer S, Saraf A Indian J Hematol Blood Transfus. 2024; 40(3):400-406.

PMID: 39011239 PMC: 11246386. DOI: 10.1007/s12288-023-01731-5.


Plasma Cell Leukemia-Clinicopathological Profile from a Tertiary Care Center in Western India.

Manimaran P, Rai V, Ranka R, Sawhney J South Asian J Cancer. 2023; 12(3):280-285.

PMID: 38047050 PMC: 10691916. DOI: 10.1055/s-0043-57231.


References
1.
Nalghranyan S, Singh A, Schinke C . The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2019; 95(2):E34-E35. DOI: 10.1002/ajh.25676. View

2.
Rojas E, Corchete L, Mateos M, Garcia-Sanz R, Misiewicz-Krzeminska I, Gutierrez N . Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Blood Cancer J. 2019; 9(12):90. PMC: 6868169. DOI: 10.1038/s41408-019-0253-1. View

3.
Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis M . Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. Am J Hematol. 2013; 89(2):145-50. DOI: 10.1002/ajh.23600. View

4.
Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M . Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique.... Blood. 2001; 97(3):822-5. DOI: 10.1182/blood.v97.3.822. View

5.
Usmani S, Nair B, Qu P, Hansen E, Zhang Q, Petty N . Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 2012; 26(11):2398-405. PMC: 3426639. DOI: 10.1038/leu.2012.107. View